Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study

Su-Mei Xu; Li-Wen Chang; Cheng-Yuan Tsai; Wan-Li Liu; Dai Li; Shan-Shan Li; Xiao-Min Li; Ping-Sheng Xu

doi:10.3389/fphar.2023.1272466

Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study

Front Pharmacol. 2023 Nov 1:14:1272466. doi: 10.3389/fphar.2023.1272466. eCollection 2023.

Authors

Su-Mei Xu^{1

2}, Li-Wen Chang³, Cheng-Yuan Tsai³, Wan-Li Liu^{1

2}, Dai Li^{1

2}, Shan-Shan Li^{1

2}, Xiao-Min Li^{1

2}, Ping-Sheng Xu^{1

2}

Affiliations

¹ Phase I Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, China.
² National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
³ TaiGen Biotechnology Co., Ltd., Taipei, China.

Abstract

Background: The cap-snatching mechanism of influenza virus mRNA transcription is strongly suppressed by TG-1000, a prodrug rapidly metabolized into TG-0527, is a potent cap-dependent nucleic acid endonuclease inhibitor. Herein, we aimed to assess the safety, tolerability, and pharmacokinetics of TG-1000 in healthy participants and the effect of food on the pharmacokinetics and safety of TG-1000. Method: The study was divided into 2 parts: Part A [Single Ascending-Dose (SAD) study, 10-160 mg] and Part B [Food-Effect (FE) study, 40 mg] were launched sequentially. The study included 66 participants for both investigations. We administered different TG-1000 capsules or placebo doses per the study protocol and collected blood samples for pharmacokinetic assessments at specific times. In plasma, TG-1000 and its active metabolite TG-0527 were assayed, and PK parameters were determined. Results: In SAD, the increase in AUC was less than the proportional increase in dose over the 20-160 mg dose range, while the increase in C_max was proportional to the increase in dose. In the 10-160 mg dose range, T_1/2, λz and T_max of TG-0527 were dose-independent; and T_1/2 and T_max were within 33.8-39.4 h and 3.02-6 h, respectively. In FE, the AUC_0-inf, AUC_0-last, and C_max of TG-0527 decreased by approximately 17.52%, 18.76%, and 41.35%, respectively, and the T_max delay was around 1.50 h. No serious adverse events occurred during the studies. Conclusion: Overall, TG-1000 was well tolerated and exhibited an acceptable safety and PK profile, supporting further clinical investigation of TG-1000 for the treatment of influenza.

Keywords: TG-1000; first-in-human; influenza; pharmacokinetics; safety; tolerability.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Natural Science Foundation of Hunan Province (2023JJ60143).